Kishimoto Ichiro, Tokudome Takeshi, Schwenke Daryl O, Takeshi Soeki, Hosoda Hiroshi, Nagaya Noritoshi, Kangawa Kenji
a Department of Biochemistry, National Cardiovascular Center Research Institute, 5-7-1 Fujishiro-dai, Suita, Osaka 565-8565, Japan.
b Department of Biochemistry, National Cardiovascular Center Research Institute, 5-7-1 Fujishiro-dai, Suita, Osaka 565-8565, Japan.
Expert Rev Endocrinol Metab. 2009 May;4(3):283-289. doi: 10.1586/eem.09.7.
It has recently been revealed that ghrelin, a hormone discovered in the stomach, has a potential therapeutic role in the treatment of diseased hearts. In human patients with heart failure and in animal models, repeated subcutaneous administration of ghrelin improves cardiac dysfunction and remodeling. Moreover, ghrelin treatment early after myocardial infarction effectively reduces fatal arrhythmia and, consequently, mortality. The beneficial effects of ghrelin result from a growth hormone increase, an orexigenic effect, direct actions to the cardiovascular cells and its potent inhibitory action on sympathetic nervous activity, which is excessively activated in cardiac diseases. These results suggest that ghrelin could be a promising novel therapeutic agent for cardiac diseases.
最近有研究表明,胃中发现的一种激素——胃饥饿素,在治疗患病心脏方面具有潜在的治疗作用。在心力衰竭的人类患者和动物模型中,重复皮下注射胃饥饿素可改善心脏功能障碍和重塑。此外,心肌梗死后早期给予胃饥饿素治疗可有效降低致命性心律失常,从而降低死亡率。胃饥饿素的有益作用源于生长激素增加、食欲增强作用、对心血管细胞的直接作用以及对交感神经活动的强效抑制作用,而交感神经活动在心脏疾病中会过度激活。这些结果表明,胃饥饿素可能是一种有前景的新型心脏病治疗药物。